<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>B-cell precursor (BCP) <z:hpo ids='HP_0001909'>leukemia</z:hpo> is the most common form of <z:e sem="disease" ids="C0278704" disease_type="Neoplastic Process" abbrv="">childhood cancer</z:e> and represents one of the most radiation-resistant forms of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we examined the antileukemic efficacy of the B43 (anti-CD19)-pokeweed antiviral protein (B43-<z:mp ids='MP_0010998'>PAP</z:mp>) immunotoxin against radiation-resistant BCP <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells </plain></SENT>
<SENT sid="2" pm="."><plain>B43-<z:mp ids='MP_0010998'>PAP</z:mp> caused <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of radiation-resistant primary BCP <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells, killed greater than 99% of radiation-resistant primary leukemic progenitor cells from BCP <z:hpo ids='HP_0001909'>leukemia</z:hpo> patients, and conferred extended survival to <z:hpo ids='HP_0004430'>severe combined immunodeficiency</z:hpo> (<z:mp ids='MP_0002536'>SCID</z:mp>) mice xenografted with radiation-resistant human BCP <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, the combination of B43-<z:mp ids='MP_0010998'>PAP</z:mp> and total body irradiation (TBI) was more effective than TBI alone in two <z:mp ids='MP_0002536'>SCID</z:mp> mouse bone marrow transplantation models of radiation-resistant human BCP <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Thus, B43-<z:mp ids='MP_0010998'>PAP</z:mp> may prove useful in the treatment of radiation-resistant BCP <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
</text></document>